HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 7249-7258

  Ortiz Muñoz, Blanca ^a   Aznar Oroval, Eduardo ^a   García, Ana García ^a   Peris, Amparo Covisa ^a   Ballestero, Pilar Perez ^a   Yepes, Marina Sanchez ^a   Lozano, Tomás Garcia ^a   Ballester, Carmen Illueca ^a   Garcia, Enrique García ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

HE4; Ovarian cancer; Pelvic mass; ROMA algorithm; Tumour markers

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4;

ADULT; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; ENDOMETRIOSIS; FEMALE; GYNECOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTIVE VALUE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK OF OVARIAN MALIGNANCY ALGORITHM; SENSITIVITY AND SPECIFICITY;

AGED; ALGORITHMS; CA-125 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; PROTEINS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905059070     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1945-6     Document Type: Article

References (41)

1. Jemal A, Siegel RXJ, Sala E. Cancer statistics. CA Cancer J Clin. 2010;60(5):277-300.
2. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Trope C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer. 2006;16 Suppl 1:11-7.
3. Engelen MJ, Kos HE, Willemse PH, Aalders JG, de Vries EG, Schaapveld M, et al. Surgery by consultant gynaecologic oncologists improves survival in patients with ovarian carcinoma. Cancer. 2006;106(3):589-98. (Pubitemid 43157622)
4. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumour markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54(12):e11-79. (Pubitemid 352777353)
5. Jacobs I, Bast Jr RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4(1):1-12. (Pubitemid 19069900)
6. Molina R, Ojeda B, Filella X, Borras G, Jo J, Mas E, et al. A prospective study of tumour markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas. Tumour Biol. 1992;13:278 - 86.
7. Molina R, Auge JM, Escudero JM, Marrades R, Vinolas N, Carcereny E, et al. Mucins CA 125, CA 19.9, CA 15.3 and TAG 72.3 as tumour markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol. 2008;29:371-80.
8. Molina R, Auge JM, Bosch X, Escudero JM, Vinolas N, Marrades R, et al. Usefulness of serum tumour markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour Biol. 2009;30:121-9.
9. Markman M. The role of CA-125 in the management of ovarian cancer. Oncologist. 1997;2:6-9. (Pubitemid 27163434)
10. Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, et al. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem. 1991;37:1379-83. (Pubitemid 21925975)
11. Menon U, Gentry-Maharaj A, Hallet R, Ryan A, Burnell M, Sharma A et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10 (4):327-340. available http://www.ncbi.nlm.nih.gov/ pubmed/21642681
12. Patridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009;113 (4):775-782. available http://www.ncbi.nlm.nih.gov/pubmed/19305319
13. Bast Jr RC, Klug TL, Schaetzl E, Lavin P, Niloff JM, Greber TF, et al. Monitoring human ovarian carcinomawith a combination of CA125, CA 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol. 1984;149:553-9. (Pubitemid 14086185)
14. Bast Jr RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumour markers: CA 125 and beyond. Int J Gynecol Cancer. 2005;15 Suppl 3:274-81. (Pubitemid 43096594)
15. van Dalen A, Favier J, Hallensleben E, Burges A, Stieber P, de Bruijn HW, et al. Significance of serum CA 125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up. Eur J Gynaecol Oncol. 2009;30:609-15.
16. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63(13):3695-700. (Pubitemid 36793054)
17. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162-9. (Pubitemid 40490123)
18. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumour biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402-8. (Pubitemid 351174295)
19. Havrilesky L, Whitehead C, Rubatt J, Cheek R, Groelke J, He Q, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008;110:374-82.
20. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast Jr RC, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010;117:440-5.
21. Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. The utility of serum human epididymis protein 4 (HE4) in patients with malignant and non malignant diseases: comparison with CA 125. Clin Chem. 2011;57(11):1534-44.
22. Galgano M, Hampton G, Frierson HJ. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847-53. (Pubitemid 43780455)
23. Moore RG, Brown AK, Craig Miller M, Badgwell D, Lu Z, Allard WJ, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008;110:196-201.
24. Hertlein L, Stieber P, Kirschenhofer A, Krocker K, Nagel D, Lenhard M, et al. Human epididymis protein (HE4) in benign and malignant diseases. Clin Chem Lab Med. 2012;50(12):2181-8.
25. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Craig Miller M, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and Ca125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40-6.
26. Park Y, Lee JH, Hong DJ, Lee EY, Kim HS. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem. 2011;44(10-11):884-8. doi:10.1016/j.clinbiochem.2011.04.011.
27. Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100:1315-9.
28. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203:228-6.
29. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99:267-77. (Pubitemid 41502830)
30. National Institute for Health and Clinical Excellence (NICE): Guidance. Ovarian cancer: the recognition and initial management of ovarian cancer. National Collaborative Centre for Cancer (UK). Cardiff, UK: National Collaborative Centre for Cancer, 2011.
31. Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, et al. Use of Symptom Idex, Ca125, and HE4 to predict ovarian cancer. Gynecol Oncol. 2010;116:378-83.
32. Lenhard M, Stieber P, Hertlein L, Kirschenhofer A, Fürst S, Mayr D, et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA 125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med. 2011;49(12):2081-8.
33. Deeks JJ, Almant DG. Diagnostics test 4: likelihood ratios. BMJ. 2004;329(7458):168-9.
34. Molina R, Escudero JM, Augé JM, Filella X, Foj L, Torne A, et al. HE4 a novel tumour marker for ovarian cancer: comparison with Ca125 and ROMA algoritm in patients with gynaecological diseases. Tumor Biol. 2011;32:1087-95.
35. Park Y, Kim Y, Lee EY, Lee JH, Kim HS. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer. 2012;130:1136-44.
36. Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and Ca125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer. 2011;104:863-70.
37. Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnositic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev. 2011;20:2496-506.
38. Yu S, Yang HJ, Xie SQ, Bao YX. Diagnostic value of HE4 for ovarian cancer: a meta-analysis. Clin Chem Lab Med. 2012;50(8):1439-46.
39. Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzolli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol. 2013;66:273-81.
40. Lin J, Qin J, Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynaecologic disease and ovarian cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2013;167(1):81-5.
41. Li F, Ruxiu T, Chang K, Wang F, Deng S, Lu W, et al. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and Ca125 in predicting epithelial ovarian cancer: A meta-analysis. BMC Cancer. 2012;12:258-76.